OEL Fastrac Catalog

Difamilast is indicated for adult atopic dermatitis. It is under investigation in a clinical trial (NCT01702181) to treat adults with atopic dermatitis in the United States. Difamilast, a phosphodiesterase 4 (PDE4) inhibitor, selectively inhibits PDE4 subtypes (PDE4A, PDE4B, PDE4C, and PDE4D), with a particularly strong effect on PDE4B. Phosphodiesterase 4 (PDE4), found in various immune cells, specifically degrades cyclic adenosine 3',5'-monophosphate (cAMP). By increasing intracellular cAMP concentration, this drug controls the production of cytokines and chemokines, thus suppressing skin inflammation. It is anticipated to be effective in treating atopic dermatitis, a condition characterized by recurring episodes of itchy eczema, as patients with atopic dermatitis often exhibit increased PDE4-like activity and decreased intracellular cAMP concentration in peripheral blood leukocytes.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Difamilast, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.